20Med Therapeutics is biomedical company developing and exploiting a portfolio of multifunctional polymer-based carriers for targeted drug delivery. 20Med Therapeutics was founded in 2011 as a spin-off company of Biomedical Chemistry group of prof. Johan Engbersen after the successful development of an innovative and a unique set of polymeric hybrid constructs (20MED-nanogels) which possess a hitherto unmet combination of properties essential for successful intracellular drug delivery in clinical applications. Due to their specialchemical construction, 20MED-nanogels are stable, well-processable, nontoxic, and biodegradable nanoparticles that can be isolated and stored in powder formulation and can be easily loaded with therapeutic payload after dissolution. Current focus is on application of the nanogels for targeted delivery of therapeutic (oligo-)nucleotides (siRNA, miRNA, mRNA, and DNA). After the nanoparticles are taken up by the cells, specific chemical functionalities within the 20MED-nanogel promote endosomal escape and efficient release of the therapeutic payload into the cytosol, resulting in high transfection and gene silencing efficiencies. The molecular architecture of 20MED-nanogels allows the introduction of different complementary binding sites inside the core of the nanogels, which gives the nanogels also high potential for intracellular delivery of small molecule drugs, peptides and proteins.